Compare SPCB & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | IPSC |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 49.8M |
| IPO Year | N/A | 2021 |
| Metric | SPCB | IPSC |
|---|---|---|
| Price | $8.90 | $0.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $18.00 | $3.00 |
| AVG Volume (30 Days) | 73.4K | ★ 840.4K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | $26,739,000.00 | ★ $113,337,000.00 |
| Revenue This Year | N/A | $1,590.09 |
| Revenue Next Year | $27.13 | N/A |
| P/E Ratio | $10.60 | ★ N/A |
| Revenue Growth | N/A | ★ 4122.69 |
| 52 Week Low | $3.14 | $0.34 |
| 52 Week High | $18.95 | $1.26 |
| Indicator | SPCB | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 64.47 |
| Support Level | $8.64 | $0.54 |
| Resistance Level | $9.92 | $0.62 |
| Average True Range (ATR) | 0.49 | 0.04 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 28.62 | 95.74 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.